Sandrine Piret‑Gerard

Sandrine Piret‑Gerard serves as Chief Commercialization Officer at argenx, where she leads the company’s Commercial and Medical Affairs & Evidence Generation organization, with a focus on driving sustainable growth and expanding patient access to argenx’s medicines worldwide.

Sandrine brings more than 20 years of global biopharmaceutical experience across the U.S. and Europe, spanning all stages of the product lifecycle and multiple therapeutic areas, including immunology, oncology, virology, cardiovascular, neuroscience, and dermatology. Prior to joining argenx, she served as Senior Vice President, U.S. Commercial at Gilead Sciences, where she was responsible for commercializing the company’s medicines in the U.S. across virology and oncology. Before Gilead Sciences, Sandrine spent nearly two decades at Novartis, holding senior leadership roles across U.S., Europe, and global commercial organizations, including leading the U.S. Solid Tumors and Hematology business and overseeing Global Marketing, Value & Access, and Portfolio Strategy for Novartis Oncology worldwide.